7"Real-World" use of cinacalcet for managing SHPT in different European countries: Analysis of data from the ECHO observational study

Clinical Nephrology

Volumn 74, Issue 3, 2010, Pages 198-208

  Vervloet, M ^a   Bencova, V ^b   Malberti, F ^c   Ashman, N ^d   Os, I ^e   Saha, H ^f   Urena P ^g   Zitt, E ^h   Rix, M ⁱ   Ryba, M ^j   Fouque, D ^k   Dehmel, B ^l,m   Petavy, F ^l,m   Jacobson, S H ⁿ  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DIA NE Sro   (Slovakia)

^c CREMONA HOSPITAL   (Italy)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g Clinique du Landy   (France)

^h Public Hospital Elisabethinen   (Austria)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j Krajska Nemocnice Liberec   (Czech Republic)

^k UNIVERSITÉ LYON 1   (France)

^l AMGEN INC   (United States)

^m AMGEN LTD   (United Kingdom)

ⁿ DANDERYD HOSPITAL   (Sweden)

more..

Author keywords

Calcimimetic; Cinacalcet; Observational study; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D; NAPHTHALENE DERIVATIVE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DATA ANALYSIS; EUROPE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM; TREATMENT RESPONSE; BLOOD; CHRONIC KIDNEY FAILURE; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; EUROPE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77957122606     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp74198     Document Type: Article

References (30)

1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. 1999; 73 (Suppl): 14-19.
2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945-1953. (Pubitemid 43924257)
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
4. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52: 519-530.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: 1-201.
6. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3: 1423-1429.
7. Moe S, Drueke T, KDIGO Group. KDIGO Clinical practice guidelines for the diagnosis, evaluation, prevention, and Treatment of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD) Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney International. 2009; 76 (Suppl): S121-S130.
8. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004; 66: 2010-2016.
9. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of parathyroidectomy in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Hemodial Int. 2007; 11: 62-71.
10. Gagne ER, Urena P, Leite-Silva S, Zingraff J, Chevalier A, Sarfati E, Dubost C, Drueke TB. Shortand long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol. 1992; 3: 1008-1017.
11. Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrol Dial Transplant. 2008; 23: 2319-2323.
12. Tominaga Y, Uchida K, Haba T, Katayama A, Sato T, Hibi Y, Numano M, Tanaka Y, Inagaki H, Watanabe I, Hachisuka T, Takagi H. More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis. 2001; 38: 168-171.
13. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
14. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium- phosphorus product. Am J Nephrol. 2003; 23: 369-379.
15. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44: 34-38.
16. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, Del Mar EG, Balandrin MF. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998; 95: 4040-4045.
17. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, CoyneDW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350: 1516-1525.
18. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, doubleblind, multicenter study. J Am Soc Nephrol. 2005; 16: 800-807.
19. Urena P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Leavey S, Rix M, Os I, Saha H, Ryba M, Bencova V, Banos A, Zani V, Fouque D. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study. Nephrol Dial Transplant. 2009; 24: 2852-2859.
20. Martin KJ, Juppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G, Campbell P, Curzi M, Charytan C, McCary LC, Guo MD, Turner SA, Bushinsky DA. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int. 2005; 68: 1236-1243.
21. Ashman N, Fouque D, Baños A, Harris C, Jacobson S. The ECHO study: the use of cinacalcet (Mimpara/Sensipar) in patients receiving/not receiving vitamin D in clinical practice XLV ERAEDTA Congress May 10 - 13, 2008, Stockholm (abstract MP407).
22. Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazao JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008; 3: 36-45.
23. St Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C, Block GA. Cinacalcet Use Patterns and Effect on Laboratory Values and Other Medications in a Large Dialysis Organization, 2004 through 2006. Clin J Am Soc Nephrol. 2009; 4: 354-360.
24. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 68: 1793-1800.
25. Aladren Regidor MJ. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. Clin Nephrol. 2009; 71: 207-213.
26. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int. 2008; 73: 300-307.
27. Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant. 2007; 22: 1828-1839.
28. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2009; 24: 982-989.
29. Terawaki H, Nakano H, Takeguchi F, Hasegawa T, Nakayama M, Okazaki M, Hosoya T. Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant. 2009; 24: 690-691; author's reply 691-692.
30. Malluche HH, Monier-Faugere MC, Wang G, Frazão JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008; 69: 269-278.